A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Dec 2016
At a glance
- Drugs BAY 1125976 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 26 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 12 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.